PuSH - Publikationsserver des Helmholtz Zentrums München: Phenolic acids from <em>Anisopus</em> mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Amadi, P.U.* ; Osuoha, J.O.* ; Ekweogu, C.N.* ; Jarad, S.J.* ; Efiong, E.E. ; Odika, P.C.* ; Ejiofor, C.* ; Aloy-Amadi, O.* ; Gill, G.S.* ; Adumekwe, C.W.* ; Gaowa, A.* ; Zhang, D.* ; de Courten, B.* ; Agomuo, E.N.*

Phenolic acids from Anisopus mannii modulates phosphofructokinase 1 to improve glycemic control in patients with type 2 diabetes: A double-blind, randomized, clinical trial.

Pharmacol. Res. 212:107602 (2025)

Verlagsversion

Forschungsdaten

DOI

PMC

	Open Access Hybrid

Abstract
Metriken
Zusatzinfos

Phenolic acid-rich fraction from Anisopus mannii (PhAM) contains abundance of ferulic acid, gallic acid, protocatechuic acid, and syringic acid. Among other glycolytic enzymes, in vitro, PhAM counteracted the binding of sodium orthovanadate to phosphofructokinase 1 (PFK-1), improving its activities. In a rat model of diet-induced diabetes, PhAM monotherapy reduced HbA1c by an average of 0.63% and fasting plasma glucose by 25mg/dl. This herb rescued β-cells from streptozotocin-mediated destruction, thereby improving glycemic control. Supported by the preclinical trial, eighty-five patients with type 2 diabetes (T2D) receiving first-line medications were enrolled in a double-blind, randomized, placebo-controlled trial with a 90% power level. Patients were randomized into a placebo group or either of the following two treatment groups: oral administration of 12mg or 20mg/kg body weight of PhAM once every 48h for 6 months. Both treatments were well tolerated. At the endpoint, more than 70% of patients achieved a 0.5 - 2.0 decrease in HbA1c levels and a >20mg/dl decrease in fasting blood glucose, meeting the pre-specified primary outcome. 66% of patients treated with 20mg PhAM achieved the < 7% HbA1c and HOMA-IR of > 1.0 goal. respectively. Our study shows that PhAM can supplement first-line medications to achieve target glycemic control within 6 months. Pan African Clinical Trial Registration number: PACTR202206531545729.

Impact Factor

Scopus SNIP

Altmetric

10.500

0.000